OncoMatch/Clinical Trials/NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Is NCT05294731 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BGB-16673 for b-cell malignancy.
Treatment: BGB-16673 — This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: unless ≥ 3 months after transplant
Prior autologous stem cell transplant unless ≥ 3 months after transplant
Cannot have received: chimeric cell therapy
Exception: unless ≥ 6 months after cell infusion
prior chimeric cell therapy unless ≥ 6 months after cell infusion
Cannot have received: allogeneic stem cell transplant
Exception: ≤ 6 months before the first dose of the study drug
prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug
Lab requirements
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify